ClinicalTrials.gg
Active, not recruitingNCT07282652Updated Jan 16, 2026

A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy

An Early Phase 1 interventional study of RAG-18 in Duchenne Muscular Dystrophy (DMD), sponsored by Peking Union Medical College Hospital. Active, not recruiting at 1 site in China. Open to male participants aged 4 Years to 15 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Peking Union Medical College Hospital · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
4 Years to 15 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Muscular Dystrophy, Duchenne with a site in China — 5 open to participants now, 10 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · China.

Planned enrollment
11th of 17
12 · median 20
Started
2025
with 1 other
Phase 1
7 of 19
3 open now
Registered
18th of 19
by date
Lead sponsor
3 of 19
Peking Union Medical College Hospital

Among the 19 studies in Muscular Dystrophy, Duchenne with a site in China, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 1, and was the 18th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 19 studies in Muscular Dystrophy, Duchenne with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 15 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Muscular Dystrophy, Duchenne with a site in China, or all of them as a file.
02

Study summary

This is an open-label, single-arm, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of RAG-18 in pediatric patients with Duchenne Muscular Dystrophy (DMD).

The study will enroll approximately 12 subjects into four cohorts to assess the safety and tolerability of ascending intravenous doses. Secondary objectives include characterizing the pharmacokinetics (PK)/pharmacodynamics (PD) profile and assessing exploratory efficacy through changes in muscle biomarkers, muscle composition, cardiac/pulmonary function, and motor performance. The decision to escalate to the next dose level will be based on a comprehensive safety evaluation of the preceding cohort.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)
04

Who can participate

Ages eligible
4 Years to 15 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) guidelines and local/national and/or Institutional Review Board (IRB)/Independent Ethics Committee (IEC) requirements, the participant and/or their legal guardian has signed the written form.
  2. Aged 4-15 years old.
  3. Male patient with Duchenne Muscular Dystrophy (DMD), able to provide a written diagnosis from a specialist and a verifiable genetic test report.
  4. Able to undergo examinations required by the study protocol, such as muscle , Magnetic Resonance Imaging (MRI), and tests for motor and pulmonary function.
  5. Any disease-related concomitant medications must be in compliance with the study's requirements.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment for Duchenne Muscular Dystrophy (DMD), regardless of whether the drug is marketed or not.
  2. (BMI) > 22 kg/m² or body weight ≥ 50 kg.
  3. Unable to complete the motor function tests required by the protocol, including: North Star Ambulatory Assessment (NSAA), Time to Stand (TTSTAND), 4-Stair Climb (4SCV), and the 6-Minute Walk Test (6MWT).
  4. Cardiac function at screening within the following ranges:

    • (LVEF) \< 55% as measured by Cardiac Magnetic Resonance (CMR).
    • corrected using Fridericia's formula (QTcF) > 450 ms at screening, or has additional risk factors for Torsades de Pointes.
  5. Hematology and electrolyte parameters at screening within the following ranges:

    • \< 100,000/μL.
    • \< 12 g/dL.
    • \< 1500/μL.
    • Any serum calcium, potassium, sodium, magnesium, or phosphorus levels outside the clinically acceptable range for Duchenne Muscular Dystrophy (DMD) patients.
    • (INR), Prothrombin Time (PT), Partial Thromboplastin Time (PTT), Activated Partial Thromboplastin Time (aPTT), or Fibrinogen outside the normal range.
  6. History of medical conditions affecting liver function, with abnormal indicators within 28 days prior to the first dose.
  7. Presence of severe cardiac, renal, or respiratory dysfunction, or other severe complications.
  8. Allergy to the study drug or any of its components, or to Magnetic Resonance Imaging (MRI) contrast agents.
  9. Receipt of a live (attenuated) vaccine within 28 days prior to the first dose of the study drug.
  10. Use of any other drug, whether for DMD or not, from 28 days prior to the first dose of the study drug until the end of the study.
  11. Any reason that, in the investigator's opinion, would prevent the participant from fully participating in and completing the study, including inability to comply with study procedures or treatment, and other relevant medical or mental health conditions.
  12. Presence of a severe concomitant condition or disease that, in the investigator's opinion, would place the participant at undue risk or interfere with the study, including but not limited to: known moderate or severe persistent asthma, a history of asthma in the past 2 years, or currently uncontrolled asthma of any classification (Note: participants with currently controlled intermittent asthma or controlled mild persistent asthma are permitted to enroll); requirement for oxygen therapy to maintain adequate blood oxygen saturation; history of (COPD) within 6 months prior to signing the Form (ICF).
  13. Participant has an unstable systemic disease as judged by the investigator, including but not limited to severe hepatic, renal, respiratory, or metabolic diseases requiring medication.
  14. Any other unspecified reason that, in the investigator's opinion, makes the participant unsuitable for enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    RAG-18

    The study will employ a dose-escalation design, enrolling participants into sequential cohorts for up to four planned dose levels. If the highest planned dose is well-tolerated, a decision to explore further dose escalation may be made based on the overall safety and risk-benefit evaluation.

    Drug: RAG-18

Interventions

  • DrugRAG-18

    RAG-18 is a therapeutic small activating RNA (saRNA) duplex molecule comprised of two partially chemically modified complementary oligonucleotide strands

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To evaluate the safety profile of RAG-18 by recording the frequency, nature, and severity of all adverse events and serious adverse events observed during the study. The relationship of these events to the study drug will be assessed.

    Time frame: From Baseline up to the end of the study (Day 169)

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of RAG-18

    To evaluate the pharmacokinetic profile of RAG-18 after intravenous infusion.

    Time frame: Day 1 and Day 85 (assessed at pre-dose, and multiple timepoints up to 168 hours post-dose)

  2. Time to Maximum Observed Plasma Concentration (Tmax) of RAG-18

    To determine the time to reach the maximum observed plasma concentration of RAG-18.

    Time frame: Day 1 and Day 85 (PK samples collected at pre-dose and multiple timepoints up to 168 hours post-dose)

  3. Area Under the Plasma Concentration-Time Curve (AUC) of RAG-18

    To determine the total drug exposure over time by calculating the Area Under the Plasma Concentration-Time Curve (AUC).

    Time frame: Day 1 and Day 85 (PK samples collected at pre-dose and multiple timepoints up to 168 hours post-dose)

  4. Terminal Half-Life (t1/2) of RAG-18

    To determine the terminal elimination half-life of RAG-18 in plasma.

    Time frame: Day 1 and Day 85 (PK samples collected at pre-dose and multiple timepoints up to 168 hours post-dose)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2026, 11 months after the start.

Of 28 phase 1 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Dec 15, 2025
StartActual
Dec 12, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07282652
Collaborators
Ractigen Therapeutics.
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Dec 12, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion